Cinclus Pharma Investor Relations Material

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company based in Stockholm, Sweden. The company specializes in the development of treatments for acid-related diseases. Its primary focus is on a drug candidate called linaprazan glurate, which is being developed for the treatment of gastroesophageal reflux disease (GERD) and Helicobacter pylori infections. Linaprazan glurate is designed as a Potassium-Competitive Acid Blocker (P-CAB), offering a potentially more effective alternative to traditional Proton Pump Inhibitors (PPIs) used in treating acid-related conditions. Cinclus Pharma Holding AB is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq Stockholm.